Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
Annals of Internal Medicine [AIM] Study on Part D
[By Staff Writers]
The AIM recently reported from its online survey that Medicare Part D induced a 13.1 % decrease in out-of-pocket expenses for patients and a 5.9 % increase in prescription drug use.
The study compared out-of-pocket costs and the number of pills purchased by those who were eligible for Part D – with comparable patients who were not. It also compared Part D members to patients who were eligible for, but did not enroll in, Medicare Part D.
The program saved pre May 15, 2006 members about $6 per month and gave them an extra three to four days worth of one medicine per month.
After the enrollment deadline, average savings among all eligible seniors increased to about $9 a month with 14 extra days of medicine per month. The study also found that patients who enrolled early in the Part D program and higher rates of utilization and out-of-pocket costs prior to the Part D period and stood to benefit most from enrollment.
Assessment
And so, what are your thoughts on these results, first reported by Newswise on January 8, 2008?
Conclusion
Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.
Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com
OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:
- PRACTICES: www.BusinessofMedicalPractice.com
- HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
- CLINICS: http://www.crcpress.com/product/isbn/9781439879900
- ADVISORS: www.CertifiedMedicalPlanner.org
- FINANCE: Financial Planning for Physicians and Advisors
- INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors
- Dictionary of Health Economics and Finance
- Dictionary of Health Information Technology and Security
- Dictionary of Health Insurance and Managed Care
[HEALTH INSURANCE, MANAGED CARE, ECONOMICS, FINANCE AND HEALTH INFORMATION TECHNOLOGY COMPANION DICTIONARY SET]
[Mike Stahl PhD MBA] *** [Foreword Dr.Mata MD CIS] *** [Dr. Getzen PhD]
***
Share this:
Filed under: Drugs and Pharma | Tagged: Big Pharma and Drugs |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
MMA 2003-2008
Did you know that enrollment in the Medicare Part D prescription drug benefit program for 2008 increased by 6.2 percent; to 25.4 million beneficiaries?
The Centers for Medicare and Medicaid Services [CMS] just reported that among the 44.2 million Medicare beneficiaries, 17.4 million enrolled in stand-alone prescription drug plans and eight million have enrolled in Medicare Advantage plans. Moreover, 14.2 million Medicare beneficiaries receive prescription drug coverage through retirement, veterans or other programs.
Currently, more than 39 million Medicare beneficiaries, or 90 percent, have prescription drug coverage through the prescription drug benefit or some other source, while the estimated cost of the Medicare prescription drug benefit through 2017 decreased by $117 billion from an estimate done last year.
-Donna
LikeLike
A health economist explains the real reason American drugs are expensive
© Provided by Vox.com
Craig Garthwaite is a health economist at Northwestern University’s Kellogg School of Business whose research often focuses on America’s pharmaceutical market.
So it’s no surprise he’s been a very interested observer of Daraprim, the generic drug that recently got a 5,500 percent price hike.
http://www.msn.com/en-us/money/insurance/a-health-economist-explains-the-real-reason-american-drugs-are-expensive/ar-AAeMz34?li=AA4Zjn&ocid=U348DHP
Melvin
LikeLike